Navigation Links
Evonik Industries Selects OPX Biotechnologies for Joint Development of Bio-Based Chemicals
Date:5/14/2013

BOULDER, Colo. and ESSEN, Germany, May, 14 2013 /PRNewswire/ -- OPX Biotechnologies, Inc. (OPXBIO) and Evonik Industries AG today announced the two companies have entered into an agreement to jointly develop certain bio-based specialty chemicals. The joint-development agreement signed May 3rd 2013 calls for OPXBIO to use its proprietary EDGE™ (Efficiency Directed Genome Engineering) technology to develop the bio-processes.

(Logo:  http://photos.prnewswire.com/prnh/20111108/CG01932LOGO)

"There's a growing market demand for more sustainable products and processes, and OPXBIO is an excellent partner to help us meet that demand because their technology can create high-value, bio-based chemicals quickly and cost-effectively," said Dr. Thomas Haas , Vice President Science-to-Business Center Biotechnology of Creavis, the strategic research and development unit of Evonik.

"Evonik is a leading global specialty chemicals company, and we're looking forward to helping them expand their portfolio of bio-based chemicals," said Charles R. (Chas) Eggert , OPXBIO president and CEO. "The bio-process we're developing has the potential to create economic and sustainable versions of products we use in our everyday lives." According to the agreement, OPXBIO will also be able to market bio-based products resulting from the Evonik collaboration.

About OPXBIO

OPX Biotechnologies (OPXBIO) is a leader in sustainably transforming the business of chemistry. As the "Good Chemistry" company, OPXBIO provides more sustainable value to customers by applying its proprietary EDGE ™ (Efficiency Directed Genome Engineering) technology to produce economic, bio-based chemicals that directly replace existing petroleum-based products. OPXBIO's EDGE is versatile and enables faster, more efficient development of bioprocesses using a variety of feedstocks. Founded in 2007, OPXBIO is financed by leading venture capital investors, and employs 65 people in Boulder, Colo.

For more information, visit www.opxbio.com and follow OPXBIO on Twitter.

About Evonik

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.6 billion and an operating profit (adjusted EBITDA) of about €2.6 billion.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.


'/>"/>
SOURCE OPX Biotechnologies Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Ben-Gurion U. researchers and Teva Pharmaceutical Industries Ltd. develop psoriasis drug
2. Service Credit Union Selects DigitalPersona to Secure Access to Network and Applications
3. RedBrick Health Launches Open Integration and Partner Certification Program, Selects Fitbit, RunKeeper Among First to be "RedBrick Ready"
4. Statistics & Data Corporation Selects MedNet Solutions As Strategic Technology Partner
5. Crank Software Selects TREW Marketing for Embedded Industry Outreach
6. EU Commission selects Human Brain Project, with Israelis as partners
7. NSF selects OSU to lead project rejuvenating US research fleet
8. The Human Frontier Science Program selects new heads of start-up laboratories
9. Silex Technology Selects TREW Marketing for Branding and Marketing Strategy Following Co-Marketing Campaign with Freescale
10. Mount Sinai Selects Exemplar LIMS for Genomics Core Facility
11. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2019)... CITY, and MARTINSRIED, Germany (PRWEB) , ... August ... ... high-throughput antibody screening and characterization, announced today that they have opened a Customer ... platform has fueled the need for the new office. , The Munich CEC ...
(Date:8/14/2019)... , ... August 13, 2019 , ... ... Team, Division of Molecular Pathology, Institute of Cancer Research (ICR) in a ... to learn about the process of biomarker and companion diagnostic development including machine ...
(Date:8/6/2019)... ... August 06, 2019 , ... ... manufacturing with clinical, regulatory and GMP manufacturing experience. In November it spun ... With extensive regulatory experience and one of the first cGMP cell ...
Breaking Biology News(10 mins):
(Date:6/26/2019)... ... ... Alice Branton today released research results from preclinical trials on the beneficial ... prove to be beneficial for treating Hypomagnesemia. , The preclinical trial shows:, ... , Over 142% increase in particle size , Over 3% ...
(Date:6/18/2019)... ... 18, 2019 , ... Personalized Stem Cells, Inc (“PSC”), a human ... FDA for use of a person’s own adipose-derived stem cells to treat their osteoarthritis. ... knee. This IND is the first of several planned clinical trials which will ...
(Date:6/11/2019)... ... June 10, 2019 , ... ... distribution network with the appointment of Biofeedback Tech Ltd as its ... are an essential part of many therapeutic treatments and clinical assessment protocols to ...
(Date:6/11/2019)... , ... June 10, 2019 , ... ... IOPP will add 80 of its scientific journals to DeepDyve’s rental service for ... to DeepDyve’s continually expanding library of more than 20 million articles, sourced from ...
Breaking Biology Technology: